The new Angiomax patent is not the critical composition-of-matter patent that MDCO has been trying to get extended through bribery and other means. I doubt that the new patent will stand up to scrutiny, and it certainly won't scare off an aggressive P-IV challenger.
Market Data 
Markets 
AI
